Showing results (331-340 of 358) with videos related to
Sort By:
Pageof 36
Science Immunology|May 5, 2023
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapyLihong Wang-Bishop, Blaise R Kimmel, Verra M Ngwa, et al.Nature Biomedical Engineering|June 11, 2025
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugatesBlaise R Kimmel, Karan Arora, Neil C Chada, et al.Nature|November 17, 2022
T cells specific for α-myosin drive immunotherapy-related myocarditisMargaret L Axelrod, Wouter C Meijers, Elles M Screever, et al.Bioorganic & Medicinal Chemistry|September 1, 2015
The discovery of Arylex™ active and Rinskor™ active: Two novel auxin herbicidesJeffrey B Epp, Anita L Alexander, Terry W Balko, et al.Cancer Immunology Research|September 28, 2016
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B Johnson, Garrett M Frampton, Matthew J Rioth, et al.Nature Communications|November 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trialAdrienne G Waks, Jingxin Fu, Xiangying Chu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast CancerMargaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.Cancer Discovery|December 21, 2013
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targetsJustin M Balko, Jennifer M Giltnane, Kai Wang, et al.Pageof 36